NICE consults on draft guidance for types of arthritis that affect the spine
The UK’s National Institute for Health and Care Excellence (NICE) has today published draft guidance on TNF-alpha inhibitors for treating some types of inflammatory arthritis that affect the spine.
The guidance covers Humira (adalimumab) from AbbVie, Enbrel (etanercept) from Pfizer, infliximab (known as Remicade from Merck & Co; and biosimilars Inflectra from Hospira and Remsima from Celltrion), Cimzia (certolizumab pegol) from UCB Pharma and Simponi (golimumab) from Merck & Co.
The draft guidance re-affirms previous NICE guidance recommending adalimumab, etanercept and golimumab as treatment options for adults with ankylosing spondylitis. The draft guidance also now recommends certolizumab pegol as an additional treatment option for adults with anklylosing spondylitis. Non-radiographic axial spondyloarthritis is also covered by the draft guidance and adalimumab, certolizumab pegol and etanercept are provisionally recommended as treatment options for adults with this condition.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze